Cancer immunotherapy, also called biologic therapy, which can predominantly be classed as a form of targeted therapy, It is designed to stimulate the body's immune system to attack tumours.

The global Cancer Immunotherapies market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Cancer Immunotherapies volume and value at global level, regional level and company level. From a global perspective, this report represents overall Cancer Immunotherapies market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Amgen
AstraZeneca
Roche
Bristol-Myers Squibb
Bayer
Merck
ARMO BioSciences (Eli Lilly)
Novartis
Pfizer
Johnson & Johnson
AbbVie
Gilead Sciences

Segment by Regions
North America
Europe
China
Japan

Segment by Type
Monoclonal Antibodies (MABs)
Cancer Vaccines
Immunomodulators
Adoptive Cell transfer
Checkpoint Inhibitors

Segment by Application
Breast Cancer
Leukemia
Lymphoma
Melanoma
Colorectal Cancer
Non-Small Cell Lung Cancer